AKT1 and neoplasm: Among the 465 eligible enrolled patients, whole exome sequencing was successfully performed on tumor tissue samples from 394 patients as previously described.15 Following the updated OS analysis, patients with mutations in the FA-PI3K-Akt pathway and IL-7 signaling pathway were associated with improved OS in the toripalimab group (interaction P = 0.006, and 0.001 respectively) compared to the interim analysis results (Supplementary Fig. 3).